Published: 21 Jul 2020
Two COVID-19 vaccine candidates, one from China and the other from the UK,
have proven safe for humans and produced strong immune reactions among patients
involved in two separate clinical trials, the Lancet medical journal announced
The first trial among more than 1,000 adults in Britain found that the
vaccine induced "strong antibody and T cell immune responses" against
the novel coronavirus. A separate trial in China involving more than 500 people
showed that most had developed widespread antibody immune response. The results
of both trials have been published on the Lancet.
The Chinese vaccine, named Ad5-nCOV, is developed by CanSino Biologics Inc and
a military research unit. The Lancet said Phase 3 trials are needed to confirm
whether the vaccine candidate effectively protects against SARS-CoV-2
The UK vaccine, called AZD1222, is developed by AstraZeneca and scientists
at Oxford University. Authors of the UK study say further clinical studies,
including in older adults, should be done with this vaccine. Current results
focus on immune response measured in the laboratory. Further testing is needed
to confirm if the vaccine effectively protects against infection.
The two are among a handful of vaccines that have shown promise in human
testing and gear up for late-stage trials, along with projects involving
Moderna, BioNTech, and Inovio Pharmaceuticals.